Compounds > yttrium radioisotopes
Page last updated: 2024-08-26

yttrium radioisotopes and Myelodysplastic Syndromes

yttrium radioisotopes has been researched along with Myelodysplastic Syndromes in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (50.00)29.6817
2010's3 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ansell, SM; Burnette, BL; Colgan, JP; Epperla, N; Habermann, TM; Inwards, DJ; Johnston, PB; Macon, WR; Markovic, SN; Micallef, IN; Nowakowski, GS; Pham, AQ; Porrata, LF; Ristow, KM; Wiseman, GA; Witzig, TE1
Baum, RP; Bodei, L; Cremonesi, M; Drozdov, I; Grana, CM; Kidd, M; Krenning, EP; Kwekkeboom, DJ; Lepensky, C; Modlin, IM; Paganelli, G1
Buttiglieri, S; Carlo-Stella, C; Devizzi, L; Di Nicola, M; Giacomini, A; Gianni, AM; Guidetti, A; Locatelli, SL; Mariani, L; Miceli, R; Passera, R; Risso, A; Ruella, M; Tarella, C; Testi, A1
Blumstein, N; Buchmann, I; Buck, AK; Bunjes, D; Döhner, H; Glatting, G; Kotzerke, J; Neumaier, B; Reske, SN; Ringhoffer, M; Schauwecker, P; Stilgenbauer, S; von Harsdorf, S; Wiesneth, M; Zenz, T1
Dierckx, RA; Otte, A1
Czuczman, MS; Darif, M; Emmanouilides, C; Gordon, LI; Molina, A; Revell, S; Vo, K; Witzig, TE1

Trials

3 trial(s) available for yttrium radioisotopes and Myelodysplastic Syndromes

ArticleYear
Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors.
    European journal of nuclear medicine and molecular imaging, 2015, Volume: 42, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Female; Humans; Leukemia, Myeloid, Acute; Lutetium; Male; Middle Aged; Myelodysplastic Syndromes; Neuroendocrine Tumors; Octreotide; Radiation Dosage; Radiopharmaceuticals; Receptors, Peptide; Yttrium Radioisotopes

2015
Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia.
    Cancer, 2011, Nov-15, Volume: 117, Issue:22

    Topics: Adult; Aged; Antibodies, Monoclonal; Bone Marrow; Female; Follow-Up Studies; Granulocyte-Macrophage Progenitor Cells; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Radioimmunotherapy; Risk; Telomere; Yttrium Radioisotopes

2011
188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study.
    British journal of haematology, 2005, Volume: 130, Issue:4

    Topics: Aged; Antibodies, Monoclonal; Antigens, CD; Antigens, Differentiation; Antilymphocyte Serum; Antineoplastic Agents; Cell Adhesion Molecules; Female; Follow-Up Studies; Hematologic Diseases; Humans; Immunosuppressive Agents; Leukemia; Lymphocyte Depletion; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Radioimmunotherapy; Radioisotopes; Radiometry; Rhenium; Stem Cell Transplantation; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Yttrium Radioisotopes

2005

Other Studies

3 other study(ies) available for yttrium radioisotopes and Myelodysplastic Syndromes

ArticleYear
Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma.
    British journal of haematology, 2017, Volume: 178, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Chemotherapy, Adjuvant; Databases, Factual; Female; Humans; Leukemia, Myeloid, Acute; Lymphoma, Follicular; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Radioimmunotherapy; Risk Factors; Rituximab; Vidarabine; Young Adult; Yttrium Radioisotopes

2017
Myelosuppressive side-effects of radioimmunotherapy of non-Hodgkin's lymphoma: is there an increased risk?
    Nuclear medicine communications, 2005, Volume: 26, Issue:12

    Topics: Alkylating Agents; Antibodies, Monoclonal; Humans; Leukemia, Myeloid, Acute; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Myelodysplastic Syndromes; Prognosis; Radioimmunotherapy; Risk; Time Factors; Yttrium Radioisotopes

2005
Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Sep-20, Volume: 25, Issue:27

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Female; Humans; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Radioimmunotherapy; Treatment Outcome; Yttrium Radioisotopes

2007